COMPANY PROFILE

Greenlight Biosciences

GreenLight Biosciences employs the Unconstrained Metabolism(R) technology platform to produce sustainable chemicals and fuels

Medford, United StatesFounded 2008Biotech & Life Sciences

Valuation $25–50M Last recorded · 2023

Revenue $1–10M Latest reported FY

Headcount 100–500 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Greenlight Biosciences

Greenlight Biosciences was founded in 2008 by Andrey Zarur and Marta Ortega-Valle with a mission to harness the power of RNA to address critical challenges in agriculture and human health. The company set out to develop innovative RNA-based solutions that could transform the way we approach pest control and crop management, aiming for a more sustainable and equitable food system.

In its journey, Greenlight Biosciences achieved a significant milestone in August 2021 by going public through a $1.2 billion SPAC merger with Environmental Impact Acquisition Corp. This move provided the company with the necessary capital to expand its research and development efforts and bring its groundbreaking products to a broader market.

Continuing its trajectory of growth and innovation, Greenlight Biosciences announced in May 2023 that it would be acquired by Fall Line Capital in a go-private transaction. This acquisition marked a new chapter for the company, allowing it to focus on long-term strategic goals without the pressures of public market fluctuations.

Throughout its history, Greenlight Biosciences has remained committed to its founding vision, leveraging RNA technology to create solutions that not only improve agricultural productivity but also promote environmental sustainability. The company's journey reflects a steadfast dedication to innovation and impact, positioning it as a leader in the field of biosciences.

MoreLess Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2008
Headquarters: Medford, United States
Employees: 179
Open positions: 1
Dealroom signal: 65.3/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology, AgriTech
Sector: Biotech & Life Sciences, Biotechnology, Crop Protection, Genetics and genomics, Chemistry, Synthetic Biology, RNA, Sustainable Development Goals
Technology: Deep Tech
Business model: Manufacturing
Client focus: b2c
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

10 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
GROWTH EQUITY VCOther financing	Mar 2025	$25M	—	Just Climate	↗
DEBTDebt	Feb 2025	$39M	—	European Investment Bank	↗

Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin
2026
2025
2024
2023
2022
2021
2020		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Greenlight Biosciences website traffic

Latest recorded traffic for Greenlight Biosciences is 3.3K monthly website visits, up 37.5% over the last three months. Greenlight Biosciences's team declined 34.4% over the past year.

Latest monthly visits3.3K 3-month web change+37.5% 1-year team growth-34.4%

Monthly website visitsMay 2017–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Quality Assurance ManagerRochester, NY · Business Intelligence · Feb 24, 2026

1 distinct opening shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
MBmk2 BiotechnologiesDevelops, produces and investigates peptides at highest purity and quality standards using a revolutionary synthesis technology	Planegg, Germany	Acquired	9	—	—
EVEvogeneBiotechnology company developing novel products for life science markets through the use of a unique CPB platform	Rehovot, Israel	Operational
VLVan Heron LabsBiotechnology startup that leverages the power of genetics, bioinformatics, and artificial intelligence (AI) to optimize cell cultures	Huntsville, United States	Operational
RERevrFormerly Tierra Biosciences. Accelerates bio-discovery using cell-free systems combined with powerful automation tools for data generation	San Leandro, United States	Operational
PBPioneer BiolabsB2B biomanufacturing company leveraging its proprietary genomic screening platform to engineer and optimize microbial cells for protein production	Provo, United States	Operational
BABactobioLondon-based biotechnology company using breakthrough technologies in synthetic biology	London, United Kingdom	Operational
EVEvonetixUr desktop DNA synthesis platform will provide the ability to synthesise DNA at unprecedented accuracy, scale and speed, accelerating scientists' ability to use synthetic biology on a scale not currently possible	Cambridge, United Kingdom	Operational
TRTriptoBIOPlatform for producing natural plant compounds	Copenhagen, Denmark	Operational